Global Insulin Glargine and Lispro Market Insights, Forecast to 2028

Lantus (insulin glargine) is an effective, long-acting insulin that provides all-day blood sugar control, but it can cause low blood sugar levels, so be sure to have a source of sugar nearby. Lowers blood sugar. Humalog (insulin lispro) is a fast-acting insulin that controls blood sugar around meal times.
Market Analysis and Insights: Global Insulin Glargine and Lispro Market
Due to the COVID-19 pandemic, the global Insulin Glargine and Lispro market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Branded Drug accounting for % of the Insulin Glargine and Lispro global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Type I Dibetes segment is altered to an % CAGR throughout this forecast period.
China Insulin Glargine and Lispro market size is valued at US$ million in 2021, while the US and Europe Insulin Glargine and Lispro are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Insulin Glargine and Lispro landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Insulin Glargine and Lispro include Sanofi S.A, Eli Lilly and Company, Biocon Limited, Cipla Limited, Gan & Lee Pharmaceutical Ltd., Julphar Diabetes LLC, Merck & Co., Novo Nordisk A/S and SAJA Pharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Insulin Glargine and Lispro Scope and Segment
Insulin Glargine and Lispro market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Insulin Glargine and Lispro market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Branded Drug
Biosimilar Drug
Segment by Application
Type I Dibetes
Type II Dibetes
By Company
Sanofi S.A
Eli Lilly and Company
Biocon Limited
Cipla Limited
Gan & Lee Pharmaceutical Ltd.
Julphar Diabetes LLC
Merck & Co.
Novo Nordisk A/S
SAJA Pharmaceuticals
Wockhardt Ltd.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE